gsk
US Equities nudge down as bond yields continue to riseTesla down over 5% in after-hours tradingAndrew Bailey hints at further Bank of England rate risesAB InBev serves up record beer volumesTesla Master Plan DisappointsMarkets in the US ended down a little yesterday with the S&P 500 falling 0.47% to 3,951.39,and the NASDAQ composite following suit closing 0.66% to 11,379.48. The fall came as 10-year bond yields in the US climbed again, flirting briefly with the psychologically important 4% level. Q4 2022 hedge fund letters, conferences and more In after-hours trading, shares in Tesla Inc (NASD...
ValueWalk
GSK plc (LON:GSK)’s revenue in the second quarter rose 13% to £6.9bn, reflecting growth across all segments but particular strength in Specialty Medicines. Excluding a one-off, non-cash £699m charge related to Pfizer Inc. (NYSE:PFE) investments and ViiV Healthcare, operating profits were up 22% to £2.0bn. Higher royalty income and sales growth more than offset the impact from a higher proportion of lower-margin Xevudy (Covid-19 solutions) sales, higher freight costs and commodity prices and increased investment in new product launches. Q2 2022 hedge fund letters, conferences and more Excluding...
ValueWalk
Haleon will list on the LSE at 8am on 18 July in a demerger from GSK plc (LON:GSK).The split will leave shareholders with one share of GlaxoSmithKline and one share of Haleon.With gross assets totalling more than £45 billion it is expected to be the largest listing in Europe in over a decade.Haleon will trade on the London Stock Exchange under the ticker symbol ‘HLN’.Haleon’s Listning On LSESusannah Streeter, senior investment and markets analyst: “This will be the largest London Stock Market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods w...
ValueWalk
GSK plc (LON:GSK) has agreed to buy Affinivax, a vaccine maker with late-stage pneumococcal vaccine candidates. The deal will cost GSK $2.1bn upfront, with a further $1.2bn expected to be paid throughout the drug development process. The deal is expected to close in the third quarter. The group’s still expecting to deliver compound annual sales growth of 5% and operating profit growth of 10%. Q1 2022 hedge fund letters, conferences and more Shares were broadly flat following the announcement. GSK To Acquire AffinivaxLaura Hoy, Equity Analyst at Hargreaves Lansdown: “GSK’s marching ahead toward...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら